Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release

@inproceedings{Garvey2014PreventionOT,
  title={Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release},
  author={W Timothy Garvey and Donna H Ryan and Robert R. Henry and Nancy J. V. Bohannon and Hermann Toplak and Michael L. Schwiers and Barbara Troupin and Wesley W. Day},
  booktitle={Diabetes care},
  year={2014}
}
OBJECTIVE To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline. RESEARCH DESIGN AND METHODS Subanalysis of a phase 3, randomized, placebo-controlled, double-blind study of overweight/obese subjects (BMI ≥27 to ≤45 kg/m(2)) with two or more comorbidities. Subjects were randomized to placebo, PHEN 7.5 mg… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 18 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

What are the pharmacotherapy options for treating prediabetes?

Expert opinion on pharmacotherapy • 2014
View 4 Excerpts
Highly Influenced

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2018 Executive Summary.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists • 2018
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Similar Papers

Loading similar papers…